Back to top

Analyst Raises 12???Month Target and Reiterates Buy on Definium After Best-in-Class MDD Trial Results and Reduced Risk Adjustment

Maxim Group analyst Michael Okunewitch has maintained their bullish stance on DFTX stock, giving a Buy rating today. Michael Okunewitch has given h...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Definium Therapeutics, Inc. (DFTX)